Invesco Ltd. Annexon, Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Annexon, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 21,270 shares of ANNX stock, worth $148,251. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,270

Previous 22,838 6.87%

Holding current value

$148,251

Previous $111,000 12.61%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$4.49 - $7.2 $7,040 - $11,289	-1,568 Reduced 6.87%	21,270 $125,000
Q2 2024 Aug 13, 2024	SELL	$4.33 - $6.79 $3.32 Million - $5.2 Million	-766,206 Reduced 97.11%	22,838 $111,000
Q1 2024 May 14, 2024	BUY	$4.03 - $7.81 $3.09 Million - $5.99 Million	767,272 Added 3524.12%	789,044 $5.66 Million
Q4 2023 Feb 12, 2024	BUY	$1.63 - $4.63 $5,348 - $15,191	3,281 Added 17.74%	21,772 $98,000
Q3 2023 Nov 13, 2023	BUY	$2.13 - $3.84 $61 - $111	29 Added 0.16%	18,491 $43,000
Q2 2023 Aug 11, 2023	BUY	$2.1 - $6.37 $38,770 - $117,602	18,462 New	18,462 $64,000
Q4 2022 Feb 13, 2023	SELL	$4.56 - $6.61 $1,486 - $2,154	-326 Reduced 0.64%	50,263 $259,000
Q3 2022 Nov 14, 2022	SELL	$3.75 - $6.63 $9,952 - $17,596	-2,654 Reduced 4.98%	50,589 $313,000
Q2 2022 Aug 15, 2022	SELL	$2.11 - $4.06 $740 - $1,425	-351 Reduced 0.65%	53,243 $201,000
Q1 2022 May 16, 2022	BUY	$2.73 - $11.94 $115,842 - $506,650	42,433 Added 380.19%	53,594 $146,000
Q4 2021 Feb 14, 2022	SELL	$11.49 - $22.0 $21,176 - $40,546	-1,843 Reduced 14.17%	11,161 $128,000
Q3 2021 Nov 15, 2021	BUY	$16.35 - $23.4 $19,930 - $28,524	1,219 Added 10.34%	13,004 $242,000
Q2 2021 Aug 17, 2021	BUY	$17.81 - $27.48 $209,890 - $323,851	11,785 New	11,785 $265,000

Others Institutions Holding ANNX

# of Institutions

158

Shares Held

101M

Call Options Held

3.61M

Put Options Held

1.08M

View Full List

About Annexon, Inc.

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $332M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

More about ANNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account